Catabasis Pharmaceuticals, Inc.

At Catabasis Pharmaceuticals, their mission is to bring hope and life-changing therapies to patients and their families. Their lead program is edasalonexent, an NF-kB inhibitor in Phase 3 development for the treatment of Duchenne muscular dystrophy.